PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 29, 2026Laboratory Medicine Online0 citationsOpen Access

Novel Truncating Variants in MYBPC3 and NF1 : A Dual-Diagnosis Case Report Highlighting the Risk of Diagnostic Overshadowing

BBByunggyu BaeSeoul St. Mary's HospitalMJMi-Hyang JungSt. Mary's HospitalJLJune LeeEulji University

Key Result

Comprehensive genetic testing identified two independent, novel truncating variants in MYBPC3 and NF1 in a 37-year-old man with coexisting severe hypertrophic cardiomyopathy and neurofibromatosis type 1.

Key Points

  • This research aims to highlight the dual diagnosis of hypertrophic cardiomyopathy and neurofibromatosis type 1 in a single patient.
  • Clinical examination and genetic testing conducted on a 37-year-old man with symptoms of HCM and NF1.
  • Identified independent heterozygous truncating variants in MYBPC3 and NF1.
  • Family history assessment to understand segregation patterns of both disorders.
  • Patient diagnosed with obstructive hypertrophic cardiomyopathy and multiple neurofibromas associated with NF1.
  • Two novel variants classified as likely pathogenic according to genetic criteria.
  • Demonstrated that HCM and NF1 represent two independent genetic disorders, not one disease spectrum.

Study Design

Type

Case Report (n=1)

Multicenter

No

Structured PICO

P
Population
37-year-old man with severe obstructive hypertrophic cardiomyopathy (HCM) and neurofibromatosis type 1 (NF1)
I
Intervention
Comprehensive genetic testing and septal myectomy
O
Outcome
Identification of genetic etiology

This case demonstrates that coexisting HCM and NF1 can result from two independent genetic variants, highlighting the risk of diagnostic overshadowing and the need for comprehensive genetic testing in complex phenotypes.

Limitations

  • Inability to perform genetic testing in affected family members, particularly the proband's parents
  • Unable to obtain more detailed family history or conduct comprehensive cascade testing across the pedigree
  • Inability to perform genetic testing in affected family members

Abstract

Hypertrophic cardiomyopathy (HCM), the most common inherited cardiomyopathy, is characterized by unexplained left ventricular hypertrophy and an increased risk of heart failure and sudden cardiac death. Neurofibromatosis type 1 (NF1) is an autosomal dominant multisystem disorder caused by germline variants in the NF1 tumor suppressor gene. Although various forms of cardiac involvement have been reported in NF1, the coexistence of HCM and NF1 in a single patient is exceptionally rare. We report a 37-year-old man with severe obstructive HCM requiring septal myectomy. During hospitalization, clinical examination revealed multiple caf-au-lait macules and cutaneous neurofibromas, consistent with NF1. Comprehensive genetic testing identified two independent, novel heterozygous truncating variants: MYBPC3 (NM₀00256. 3: c. 1840₁843dup;p. (Ser615IlefsTer24) ), consistent with HCM, and NF1 (NM₀01042492. 3: c. 4845del;p. (Gly1616ValfsTer8) ), responsible for NF1. Both variants were classified as likely pathogenic according to American College of Medical Genetics and Genomics criteria. Family history showed distinct segregation patterns for NF1 and HCM, supporting the interpretation that these conditions represent two independent genetic disorders rather than a single disease spectrum. This case highlights the clinical challenge of a 'Dual Diagnosis. 'When a patient presents with complex, multisystemic phenotypes, attributing all symptoms to a single unifying cause may result in diagnostic overshadowing. Careful assessment of each major phenotype, along with comprehensive genetic testing, is essential to establish a complete diagnosis and to enable accurate genetic counseling and cascade screening for at-risk relatives.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Bae et al. (2026) conducted a case report in Hypertrophic cardiomyopathy and Neurofibromatosis type 1 (n=1). Comprehensive genetic testing was evaluated. Comprehensive genetic testing identified two independent, novel truncating variants in MYBPC3 and NF1 in a 37-year-old man with coexisting severe hypertrophic cardiomyopathy and neurofibromatosis type 1.

synapsesocial.com/papers/69c8c30dde0f0f753b39da1dhttps://doi.org/10.47429/lmo.2026.16.2.174
Ask AI
Helpful
Bookmark
Share
View Full Paper